Objective:To evaluate the safety and efficacy of domestic cefepime in the treatment of lower-respiratory tract bacterial infections.Methods:A double-blind

randomized control clinical trial of intravenous cefepime on patients with lower-respiratory tract bacterial infections were conducted.The regimen of the two groups were 2g

twice daily for 7 to14ds.Both drugs were given intravenously.Results:In this trial

30 patients were enrolled in trial group and other 30 patients were enrolled in control group.The overall efficacy rates and cure rate in trial and control group were 93.33%?63.33% and 96.67%?70% respectively.The bacterial clearance rates were 96% and 100% respectively

and the adverse drug reaction rates were 3.3% and 0%. There was no statistical significant differences in the above results between the two groups.The activity of cefepime against gram-positive organisms was generally higher than that of the other 4 antibacterial agents.Conclusion:The results suggested that demostic cefepime with powerful antibacterial activity and wide spectrum has the same safety and efficacy as imported one in treating lower-respiratory tract bacterial infections.